Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.1.1 Inclination of pharmaceutical companies to switch from Rx to OTC drugs
4.1.2 Favorable regulatory framework
4.1.3 Immense cost savings
4.1.4 High Penetration in emerging markets
4.1.5 Product Innovation
4.2 Restraints
4.2.1 Incorrect self-diagnosis
4.2.2 Lack of awareness among the rural regions
4.2.3 Probability of substance abuse
4.3 Opportunities
4.3.1 Increasing Need for Over-the-Counter Drugs
4.4 Challenges
4.4.1 Lack of valid literature
4.4.2 High expenditure on advertisements
4.4.3 Counterfeit drugs
Chapter 5 Market Segmentation, By Product Category
5.1 Cough and Cold
5.2 Analgesics
5.3 Vitamin, Minerals, and Supplements
5.4 Dermatological Products
5.5 Gastrointestinal Products
5.6 eight Loss/Dietary Products
5.7 Ophthalmic Products
5.8 Sleep Aids
5.9 Smoking Cessation Aids
5.10 Others
Chapter 6 Market Segmentation, By Geography
6.1 Introduction
6.2 Europe
6.2.1 UK
6.2.2 Scandinavia
6.2.3 Italy
6.2.4 Spain
6.2.5 France
6.2.6 Rest of Europe
Chapter 7 Competitive Landscape
7.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
7.2 Market Share Analysis
7.3 Strategies Adopted By Top Companies
Chapter 8 Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
8.1. Perrigo UK
8.1.1. Company Overview
8.1.2. Business Segments
8.1.3. Financial Performance (Public Enterprises)
8.1.4. SWOT Analysis
8.2. Alinter Limited
8.3. Mylan
8.4. Crescent Pharma
8.5. Thornton & Ross
8.6. Galderma
8.7. MCM Klosterfrau Healthcare Group
8.8. Teva
8.9. Merck Netherlands
8.10. Nefarma
8.11. Apotex
8.12. Navamedic
8.13. Medlite AS
8.14. Farenta
8.15. Weifa
Chapter 9 Market Insights
9.1 Insights of Industry Experts
9.2 Analyst Opinion (Market Understanding)
9.3 Investment Opportunities
Chapter 10 Appendix
10.1 List of Tables
10.2 List of Figures
